Author: BusinessWire

–LabVantage LIMS 8.6 Design Framework Addresses the Nature of Data Vulnerability and Best Responses–
–Internal Hackathon and Third-Party Validation Eliminate Known Potential Security Issues–
–LabVantage Emphasizes Cybersecurity Culture Throughout its …

–LabVantage LIMS 8.6 Design Framework Addresses the Nature of Data Vulnerability and Best Responses–
–Internal Hackathon and Third-Party Validation Eliminate Known Potential Security Issues–
–LabVantage Emphasizes Cybersecurity Culture Throughout its …

–LabVantage LIMS 8.6 Design Framework Addresses the Nature of Data Vulnerability and Best Responses–
–Internal Hackathon and Third-Party Validation Eliminate Known Potential Security Issues–
–LabVantage Emphasizes Cybersecurity Culture Throughout its …

—Introduces Vendor Validation to Its SaaS LIMS—
—Validation Addresses Unique Needs of Organizations in Sectors with Stringent Regulatory Requirements—
—Validation Documents That the System Meets Optimal Standards for Data Integrity and Control—
SOMERS…

—Seamlessly Integrates with LabVantage LIMS Platform to Provide Wide Range of Actionable Business Insights—
—Turnkey Application Leverages Artificial Intelligence and Machine Learning Capabilities to Deliver a Comprehensive, In-Depth View of Laborator…

—Seamlessly Integrates with LabVantage LIMS Platform to Provide Wide Range of Actionable Business Insights—
—Turnkey Application Leverages Artificial Intelligence and Machine Learning Capabilities to Deliver a Comprehensive, In-Depth View of Laborator…

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced two n…

— Follows recent appointments of Barbara Kosacz and Matthew Fust to ArsenalBio’s Board of Directors and Ken Drazan as Chairman of the Board —

— Expansion of leadership will support programmable cell therapy pioneer’s continued pipeline, business a…

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced two n…

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna Inc., Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Shannon Thyme Klinger will join the Company as Chief Legal Officer, e…